middle.news
How Is Botanix Turning $5.76M Revenue Into a Path to Profitability?
4:45am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Is Botanix Turning $5.76M Revenue Into a Path to Profitability?
4:45am on Saturday 30th of August, 2025 AEST
Key Points
Revenue surged 857% to $5.76 million, led by Sofdra sales and royalties
Net loss widened to $86.4 million due to expanded manufacturing and marketing costs
Sofdra prescriptions grew 323.5% quarter-on-quarter with expanding prescriber base
Strong cash reserves of $65 million plus undrawn debt facility support growth plans
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Botanix Pharmaceuticals (ASX:BOT)
OPEN ARTICLE